Merck Sharp + Dohme Corp.

Hong Dong Chu

Jason M Cox

Jacqueline D Hicks

Matthew Lombardo

Brian Alexander McKittrick

Sung-Sau So

Zhicai Wu

John S Debenham

Peter Orth

Clare London

Brent Whitehead

Ping Lan

Jerry Andrew Taylor

Zhongxiang Sun

Tesfaye Biftu

William K Hagmann

Ann E Weber

Hong Shen

Srikanth Venkatraman

Jinlong Jiang

Danqing D Feng

Fa-Xiang Ding

Haifeng Tang

Guoqing Li

Xin Gu

Jing Su

Li Xiao

Shuzhi Dong

Mariappan Chelliah

Ashwin Umesh Rao

Unmesh G Shah

Christopher Joseph Sinz

Weidong Pan

Haiqun Tang

Zhiqiang Zhao

Dexi Yang

Mihir Mandal

Sathesh P Bhat

Katherine Young

Henry M Vaccaro

Shu-Wei Yang

Markus Kristofer Dahlgren

Dipshikha Biswas

Revathi Reddy Katipally

Keith A Eagen

Xiaoqing Han

Reynalda DeJesus

David N Hunter

Michael A Plotkin

Amy Bittner McCracken

Jonathan E Gable

Alex Pasternak

Amy Bittner Mccracken

Brent R Whitehead

Reynalda Dejesus

Keith Eagen

Unmesh Shah

Skikanth Venkatraman

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors. 

Factor XIIa inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors. 

The present invention relates to compounds of formula (I) that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

Metallo-beta-lactamase inhibitors

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included. 

Substituted spiropiperidinyl compounds useful as GPR120 agonists

The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof that are possible useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I). 

Mineralocorticoid receptor antagonists

The present invention is directed to novel substituted aminopiperidines of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-&#xcf;V enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. 

Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes

Growing community of inventors

Livingston, NJ, United States of America

Hong Dong Chu